Amphastar Pharma (AMPH) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- US stock futures rise as investors assess Democrats' midterm sweep
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts AMPH Hot Sheet
Join SI Premium – FREE
Amphastar Pharma (NASDAQ: AMPH) reported Q3 EPS of $0.10, $0.03 better than the analyst estimate of $0.07. Revenue for the quarter came in at $80.1 million versus the consensus estimate of $78.53 million.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Timken (TKR) Tops Q3 EPS by 17c, Offers FY26 EPS Guidance
- ESAB Corporation (ESAB) Misses Q3 EPS by 3c ; Offers Guidance
- Zimmer Biomet Holdings (ZBH) Tops Q3 EPS by 2c; updates guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
